Automated hybridization assays for pharmacokinetic (PK) measurements of oligonucleotides

Oligonucleotide therapeutics such as antisense oligonucleotides (ASO) are transforming drug development, but they introduce analytical challenges especially the need for highly sensitive, broad‑range PK measurements across complex biological matrices like serum and tissue homogenates. Hybridization‑based assays must also contend with sequence‑dependent variability and structural interferences.

Discover how automated dual‑hybridization and nuclease‑dependent cutting assays on the Gyrolab^® platform provide a streamlined, sensitive solution that supports scientists and researchers in reliably quantifying ASO across diverse preclinical and clinical samples.